Our study, for the first time, reveals that the dual effects of DNA tumor virus oncogenes on tumor progression and chemotherapy response are mediated by the PERK, which indicates that targeting PERK may serve as an attractive therapeutic strategy for NPC and cervical cancer treatment. Here, EIF2AK3 is linked to cervical cancer.